Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5881-5890

  Dondossola, Eleonora ^a   Gasparri, Anna Maria ^a   Colombo, Barbara ^a   Sacchi, Angelina ^a   Curnis, Flavio ^a   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; DOXORUBICIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; NGR TUMOR NECROSIS FACTOR; OMEPRAZOLE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; LYMPHOMA; MACROMOLECULE; MELANOMA; MONOLAYER CULTURE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL MEMBRANE PERMEABILITY; CHROMOGRANIN A; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LYMPHOMA; MELANOMA; MELPHALAN; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052203877     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1273     Document Type: Article

References (50)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.(Pubitemid 44140857)
2. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
3. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
4. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Inv 2002;110:475-82.(Pubitemid 34919701)
5. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867-74. (Pubitemid 34126966)
6. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80. (Pubitemid 28063372)
7. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.(Pubitemid 30094573)
8. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006;12:175-82.(Pubitemid 43166192)
9. Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer- Bonte JN, et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009;101:219-24.
10. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010;28:2604-11.
11. Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 2010;46:198-206.
12. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010;103:837-44.
13. Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, et al. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol 2011;22:973-8.
14. Corti A,Pastorino F,Curnis F, Arap W,Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev 2011 Feb 1. doi: 10.1002/med.20238. [Epub ahead of print].
15. Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 2004;18:554-6.
16. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007;64:2863-86.(Pubitemid 351152248)
17. Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, et al. Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci 2010;67:2107-18.
18. Blois A, Srebro B, Mandalà M, Corti A, Helle KB, Serck-Hanssen G. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Reg Pept 2006;135:78-84.(Pubitemid 43816103)
19. Belloni D, Scabini S, Foglieni C, Veschini L, Giazzon A,ColomboB, et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 2007;21:3052-62.(Pubitemid 47565526)
20. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. New Engl J Med 1984;311:764-70.(Pubitemid 14026227)
21. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002;23:967-74.(Pubitemid 35203876)
22. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007;28:1117-27.(Pubitemid 47343865)
23. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. New Engl J Med 2003;348:1134-49.(Pubitemid 36337325)
24. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor alpha in heart failure. Adv Exp Med Biol 2000;482:351-9.(Pubitemid 32174544)
25. Zhang D, Lavaux T, Sapin R, Lavigne T, Castelain V, Aunis D, et al. Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med 2009;41:38-44.
26. O'Connor DT, Mahata SK, Taupenot L, Mahata M, Livsey Taylor CV, Kailasam MT, et al. Adv Exp Med Biol 2000;482:377-88.
27. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004;39:969-73.(Pubitemid 39388461)
28. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basalchromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198-202.(Pubitemid 27105292)
29. Corti A. Chromogranin A and the tumor microenvironment. Cell Mol Neurobiol 2010;30:1163-70.
30. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:111-34, viii.
31. Spadaro A, Ajello A, Morace C, Zirilli A, D'Arrigo G, Luigiano C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 2005;11:1987-90.(Pubitemid 40520997)
32. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with lowdosages of the proton-pumpinhibitoromeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303.(Pubitemid 38443779)
33. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999;13:145-53.(Pubitemid 29090008)
34. Corti A, Sanchez LP, Gasparri A, Flavio C, Longhi R, Brandazza A, et al. Production and structure characterization of recombinant chromogranin A N-terminal fragments (vasostatins): evidence of dimermonomer equilibria. Eur J Biochem 1997;248:692-9.(Pubitemid 27400022)
35. Corti A, Longhi R, Gasparri A, Chen F, Pelagi M, Siccardi AG. Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Eur J Biochem 1996;235:275-80.(Pubitemid 26045443)
36. Ratti S, Curnis F, Longhi R, Colombo B, Gasparri A, Magni F, et al. Structure-activity relationships of chromogranin A in cell adhesion. Identification and characterization of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000;275:29257-63.(Pubitemid 32043794)
37. Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, et al. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer 2007;110:845-53.(Pubitemid 47257663)
38. Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989;169:1977-91. (Pubitemid 19162960)
39. Nwariaku FE, Chang J, Zhu X, Liu Z, Duffy SL, Halaihel NH, et al. The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock 2002;18:82-5.
40. Hordijk PL, Anthony E, Mul FP, Rientsma R, Oomen LC, Roos D. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci 1999;112:1915-23.(Pubitemid 29338816)
41. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001;33:32-5.(Pubitemid 32613575)
42. Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000;14:15-22.(Pubitemid 30058156)
43. Vaingankar SM, Li Y, Biswas N, Gayen J, Choksi S, Rao F, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens 2010; 28:817-25.
44. Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, Tota B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen Comp Endocrinol 2004;136:217-24.(Pubitemid 38340784)
45. Portel-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol 2001;25:1261-7.(Pubitemid 32917119)
46. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427-43.
47. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112:521-6.(Pubitemid 351186193)
48. Johnson PW, Joel SP, Love S, Butcher M, Pandian MR, Squires L, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993;67:760-6.(Pubitemid 23101555)
49. Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347-52.
50. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. Firstline chemotherapy with capecitabine and temozolomide in patients with metastaticpancreatic endocrinecarcinomas.Cancer2011;117:268-75.